A non-biased screen revealed that while PI3K/AKT/mTOR inhibitorsefficiently kill Pten/p53-deficient tumors, the most potent drugs target JNK, which was previouslylinked to Pten-deficient cancer, and eEF2K, a kinase that controls protein translation downstream ofmTOR. This evidence concerns the gene AKT1 and cancer.